Sugi Predict

Sugi Predict / Targets / SLC5A11

SLC5A11

Sodium/myo-inositol cotransporter 2 · Q8WWX8 · SLC5A11 on Sugi Atlas →

4,266 patent compounds predicted against SLC5A11, 3,775 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Dapagliflozin Dapagliflozin (SCHEMBL157820) 1.00 1/20
Dapagliflozin Dapagliflozin (SCHEMBL165603) 1.00 1/20
Dapagliflozin Dapagliflozin (SCHEMBL499725) 1.00 1/20
SCHEMBL1302966 SCHEMBL1302966 0.83 1/20
SCHEMBL1303424 SCHEMBL1303424 0.83 1/20
SCHEMBL1036564 SCHEMBL1036564 0.82 1/20
SCHEMBL1666939 SCHEMBL1666939 0.82 1/20
SCHEMBL1551970 SCHEMBL1551970 0.81 1/20
SCHEMBL207789 SCHEMBL207789 0.78 1/20
SCHEMBL1713525 SCHEMBL1713525 0.76 1/20
SCHEMBL302032 SCHEMBL302032 0.76 1/20
Bexagliflozin Bexagliflozin (SCHEMBL302200) 0.76 1/20
SCHEMBL303076 SCHEMBL303076 0.76 1/20
SCHEMBL499192 SCHEMBL499192 0.76 1/20
SCHEMBL499924 SCHEMBL499924 0.76 1/20
SCHEMBL302251 SCHEMBL302251 0.75 1/20
SCHEMBL500046 SCHEMBL500046 0.75 1/20
SCHEMBL796771 SCHEMBL796771 0.75 1/20
SCHEMBL2149074 SCHEMBL2149074 0.75 1/20
SCHEMBL900193 SCHEMBL900193 0.74 1/20

Clinical trials — most relevant to SLC5A11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure PHASE4RECRUITING
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients PHASE4COMPLETED
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. PHASE4COMPLETED
Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy PHASE4COMPLETED
Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study PHASE4RECRUITING
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction PHASE4COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin PHASE3COMPLETED
Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus PHASE3UNKNOWN
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction PHASE3COMPLETED
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes PHASE2COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin PHASE2NOT_YET_RECRUITING
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM). PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients nanUNKNOWN
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients nanCOMPLETED
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore nanCOMPLETED
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. nanRECRUITING
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS nanNOT_YET_RECRUITING
Optimizing Care for Diabetic Patients in Hospitalized Rehabilitation Through Structured Education nanNOT_YET_RECRUITING
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment nanCOMPLETED
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy nanUNKNOWN
ISGLT2 in Patients Without DM With Acute MI nanCOMPLETED
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) nanUNKNOWN
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes nanCOMPLETED
Dapagliflozin in the Treatment of Heart Failure nanUNKNOWN
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events nanCOMPLETED
Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes nanCOMPLETED
Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk nanCOMPLETED
New Biomarkers and Difficult-to-treat Hypertension nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC5A11 binder may also engage these)

ProteinNameSimilarity
Q3ZC26 — 1.000 Q3ZC26 →
Q2M3M2 — 1.000 Q2M3M2 →
Q8K0E3 — 1.000 Q8K0E3 →
Q9Z1F2 — 1.000 Q9Z1F2 →
Q28728 — 0.998 Q28728 →
Q5SWY8 — 0.998 Q5SWY8 →
A8I1B9 — 0.998 A8I1B9 →
Q923I7 — 0.997 Q923I7 →
A8WHP3 — 0.996 A8WHP3 →
Q8VDT1 — 0.996 Q8VDT1 →
P26430 — 0.995 P26430 →
SLC5A2 Sodium/glucose cotransporter 2 0.993 landscape →
Q91ZP4 — 0.992 Q91ZP4 →
P53793 — 0.992 P53793 →
Q9ET37 — 0.991 Q9ET37 →
P53792 — 0.990 P53792 →
Q9NY91 — 0.989 Q9NY91 →
P11170 — 0.989 P11170 →
Q9JKZ2 — 0.987 Q9JKZ2 →
A0PJK1 — 0.987 A0PJK1 →
P31636 — 0.986 P31636 →
P31637 — 0.986 P31637 →
SLC5A1 Sodium/glucose cotransporter 1 0.985 landscape →
Q8UWF0 — 0.985 Q8UWF0 →
Q8C3K6 — 0.985 Q8C3K6 →
Q6R4Q5 — 0.984 Q6R4Q5 →
P53790 — 0.984 P53790 →
P53794 — 0.984 P53794 →
P26429 — 0.983 P26429 →
P53791 — 0.983 P53791 →